Qin Jia-Yin, Liu Yan, Wang Tao
Department of Ophthalmology, Peking University International Hospital, Beijing 102206, China.
Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Int J Ophthalmol. 2025 Jan 18;18(1):94-102. doi: 10.18240/ijo.2025.01.11. eCollection 2025.
To evaluate the efficacy and safety of microcatheter-assisted 360-degree trabeculotomy combined with trabeculectomy (MATT-Trab) for treating refractory glaucoma.
Patients with refractory glaucoma who underwent MATT-Trab were retrospectively examined. Efficacy indicators for research statistics included the intraocular pressure (IOP) level, degree of decrease, changes in medication dosage, and success rate. Safety indicators included the best-corrected visual acuity and incidence of complications.
This study comprised 31 patients, including 11 males and 20 females, with ages ranging from 8mo to 67y (mean age: 29.40±22.10y). The average postoperative IOP at 1d, 1wk, 1mo, 3mo, 6mo, 1y, and the last follow-up was significantly lower than the average preoperative IOP (31.33±9.24 mm Hg, <0.05). The average number of postoperative medications at 1y was 0.48±1.51, which was significantly reduced compared to that used preoperatively (3.77±0.99, =0.00). The absolute and qualified success rates were 45.16% and 83.87%, respectively. Visual acuity exhibited no statistically significant difference between the postoperative and preoperative follow-up time points, except for the first day after surgery. The most common postoperative complications were anterior chamber hemorrhage (25 cases, 86.21%) and high IOP (10 cases, 34.48%).
Our results indicate that MATT-Trab is effective and safe for treating refractory glaucoma.
评估微导管辅助360度小梁切开术联合小梁切除术(MATT-Trab)治疗难治性青光眼的疗效和安全性。
对接受MATT-Trab治疗的难治性青光眼患者进行回顾性研究。研究统计的疗效指标包括眼压(IOP)水平、降低程度、药物剂量变化和成功率。安全性指标包括最佳矫正视力和并发症发生率。
本研究共纳入31例患者,其中男性11例,女性20例,年龄8个月至67岁(平均年龄:29.40±22.10岁)。术后1天、1周、1个月、3个月、6个月、1年及最后一次随访时的平均眼压均显著低于术前平均眼压(31.33±9.24 mmHg,P<0.05)。术后1年的平均用药次数为0.48±1.51次,与术前相比显著减少(3.77±0.99次,P=0.00)。绝对成功率和合格成功率分别为45.16%和83.87%。除术后第一天外,术后和术前随访时间点的视力无统计学显著差异。术后最常见的并发症是前房出血(25例,86.21%)和高眼压(10例,34.48%)。
我们的结果表明,MATT-Trab治疗难治性青光眼有效且安全。